泰励生物医药

Taily Bio is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics. The company leverages its proprietary Taily-Lego technology platform, which utilizes modular drug design to create highly selective and potent molecules for oncology and autoimmune disorders. Its lead candidate, TLB-101, is a next-generation tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 insertion mutations, currently undergoing clinical evaluation for non-small cell lung cancer. Taily Bio focuses on addressing unmet medical needs by targeting traditionally undruggable proteins and overcoming resistance to existing therapies. The company is led by experienced industry veterans and is supported by top-tier venture capital investors including Sequoia China and Matrix Partners China.